123 related articles for article (PubMed ID: 9871675)
1. Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent Brequinar Sodium.
Pitts WJ; Jetter JW; Pinto DJ; Orwat MJ; Batt DG; Sherk SR; Petraitis JJ; Jacobson IC; Copeland RA; Dowling RL; Jaffee BD; Gardner TL; Jones EA; Magolda RL
Bioorg Med Chem Lett; 1998 Feb; 8(3):307-12. PubMed ID: 9871675
[TBL] [Abstract][Full Text] [Related]
2. Heteroatom- and carbon-linked biphenyl analogs of Brequinar as immunosuppressive agents.
Batt DG; Petraitis JJ; Sherk SR; Copeland RA; Dowling RL; Taylor TL; Jones EA; Magolda RL; Jaffee BD
Bioorg Med Chem Lett; 1998 Jul; 8(13):1745-50. PubMed ID: 9873427
[TBL] [Abstract][Full Text] [Related]
3. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
[TBL] [Abstract][Full Text] [Related]
7. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Knecht W; Henseling J; Löffler M
Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
[TBL] [Abstract][Full Text] [Related]
9. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
10. Isoxazolylthioamides as potential immunosuppressants a combinatorial chemistry approach.
Albert R; Knecht H; Andersen E; Hungerford V; Schreier MH; Papageorgiou C
Bioorg Med Chem Lett; 1998 Aug; 8(16):2203-8. PubMed ID: 9873513
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.
Sainas S; Pippione AC; Giorgis M; Lupino E; Goyal P; Ramondetti C; Buccinnà B; Piccinini M; Braga RC; Andrade CH; Andersson M; Moritzer AC; Friemann R; Mensa S; Al-Kadaraghi S; Boschi D; Lolli ML
Eur J Med Chem; 2017 Mar; 129():287-302. PubMed ID: 28235702
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria.
Jöckel J; Wendt B; Löffler M
Biochem Pharmacol; 1998 Oct; 56(8):1053-60. PubMed ID: 9776318
[TBL] [Abstract][Full Text] [Related]
13. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA
Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain.
Hansen M; Le Nours J; Johansson E; Antal T; Ullrich A; Löffler M; Larsen S
Protein Sci; 2004 Apr; 13(4):1031-42. PubMed ID: 15044733
[TBL] [Abstract][Full Text] [Related]
15. New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold.
Lolli ML; Giorgis M; Tosco P; Foti A; Fruttero R; Gasco A
Eur J Med Chem; 2012 Mar; 49():102-9. PubMed ID: 22245049
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine.
Thomson TA; Spinella-Jaegle S; Francesconi E; Meakin C; Millet S; Flao KL; Hidden H; Ruuth E
Scand J Immunol; 2002 Jul; 56(1):35-42. PubMed ID: 12100469
[TBL] [Abstract][Full Text] [Related]
17. Dihydroorotate dehydrogenase. Profile of a novel target for antiproliferative and immunosuppressive drugs.
Löffler M; Grein K; Knecht W; Klein A; Bergjohann U
Adv Exp Med Biol; 1998; 431():507-13. PubMed ID: 9598119
[No Abstract] [Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel substituted benzamide derivatives bearing a 1,2,3-triazole moiety as potent human dihydroorotate dehydrogenase inhibitors.
Lu K; Cai L; Zhang X; Wu G; Xu C; Zhao Y; Gong P
Bioorg Chem; 2018 Feb; 76():528-537. PubMed ID: 29316525
[TBL] [Abstract][Full Text] [Related]
19. Biaryl analogues of teriflunomide as potent DHODH inhibitors.
Erra M; Moreno I; Sanahuja J; Andrés M; Reinoso RF; Lozoya E; Pizcueta P; Godessart N; Castro-Palomino JC
Bioorg Med Chem Lett; 2011 Dec; 21(24):7268-72. PubMed ID: 22078215
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Cleaveland ES; Zaharevitz DW; Kelley JA; Paull K; Cooney DA; Ford H
Biochem Biophys Res Commun; 1996 Jun; 223(3):654-9. PubMed ID: 8687451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
